TSC2 and primitive neuroectodermal tumor: At a population level, mutations in TSC2 are associated with more severe disease, including significant hamartomas, subependymal nodules, subependymal giant cell tumors, early-onset kidney disease, and pancreatic neuroendocrine tumors (PNET), and present with clinical symptoms at a younger age [2, 3, 5, 9].